{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:03:07Z","timestamp":1768345387555,"version":"3.49.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              <jats:italic>Bacillus anthracis<\/jats:italic>\n              , the causative agent of anthrax, is among the most likely bacterial pathogens to be used in a biological attack. Inhalation anthrax is a serious, life-threatening form of infection, and the mortality from acute inhaled anthrax can approach 100% if not treated early and aggressively. Food and Drug Administration-approved antibiotics indicated for post-exposure prophylaxis (PEP) or treatment of anthrax are limited. This study assessed the\n              <jats:italic>in vitro<\/jats:italic>\n              activity and\n              <jats:italic>in vivo<\/jats:italic>\n              efficacy of omadacycline and comparators against clinical isolates of\n              <jats:italic>B. anthracis,<\/jats:italic>\n              including a ciprofloxacin-resistant isolate. Minimum inhibitory concentrations (MICs) of omadacycline, ciprofloxacin, and doxycycline were determined against animal and human clinical isolates of\n              <jats:italic>B. anthracis<\/jats:italic>\n              , including the ciprofloxacin-resistant Ames strain BAC\n              <jats:sup>r<\/jats:sup>\n              4-2. Mice were challenged with aerosolized BAC\n              <jats:sup>r<\/jats:sup>\n              4-2 spores, and survival was monitored for 28 days post-challenge. Treatment was initiated 24 h after aerosol challenge and administered for 14 days. Omadacycline demonstrated\n              <jats:italic>in vitro<\/jats:italic>\n              activity against 53\n              <jats:italic>B. anthracis<\/jats:italic>\n              isolates with an MIC range of \u22640.008\u20130.25 \u00b5g\/mL, and an MIC\n              <jats:sub>50<\/jats:sub>\n              \/MIC\n              <jats:sub>90<\/jats:sub>\n              of 0.015\/0.03 \u00b5g\/mL. Consistent with this, omadacycline demonstrated\n              <jats:italic>in vivo<\/jats:italic>\n              efficacy in a PEP mouse model of inhalation anthrax caused by the Ames BAC\n              <jats:sup>r<\/jats:sup>\n              4-2 ciprofloxacin-resistant\n              <jats:italic>B. anthracis<\/jats:italic>\n              isolate. Omadacycline treatment significantly increased survival compared with the vehicle control group and the ciprofloxacin treatment group. As antibiotic resistance rates continue to rise worldwide, omadacycline may offer an alternative PEP or treatment option against inhalation anthrax, including anthrax caused by antibiotic-resistant\n              <jats:italic>B. anthracis<\/jats:italic>\n              .\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00595-24","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T13:01:30Z","timestamp":1723467690000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Omadacycline is active\n            <i>in vitro<\/i>\n            and\n            <i>in vivo<\/i>\n            against ciprofloxacin-resistant\n            <i>Bacillus anthracis<\/i>"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4746-4892","authenticated-orcid":false,"given":"Henry S.","family":"Heine","sequence":"first","affiliation":[{"name":"University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-7332","authenticated-orcid":false,"given":"George","family":"Drusano","sequence":"additional","affiliation":[{"name":"University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bret K.","family":"Purcell","sequence":"additional","affiliation":[{"name":"University of Florida, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-6320","authenticated-orcid":false,"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7206a1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050370"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0563"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_3_2_6_2","first-page":"49","article-title":"The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know?","volume":"3","author":"Kim GK","year":"2010","unstructured":"Kim GK. 2010. The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know? J Clin Aesthet Dermatol 3:49\u201354.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a816"},{"key":"e_1_3_2_8_2","unstructured":"U.S. Food and Drug Administration (FDA). 2016. CIPRO (Ciprofloxacin) - highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019537s086lbl.pdf"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.embor860"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1215773"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_14_2","unstructured":"U.S. Food and Drug Administration (FDA). 2021. NUZYRA (Omadacycline) - highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209816s011 209817s010lbl.pdf"},{"key":"e_1_3_2_15_2","unstructured":"U.S. Food and Drug Administration. 2023. Animal rule approvals. Available from: https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/animal-rule-approvals#:~:text=The%20use%20of%20the%20Animal %2C%20radiological%2C%20or%20nuclear%20substances"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00788-17"},{"key":"e_1_3_2_20_2","volume-title":"CLSI document M7-A11","author":"Clinical and Laboratories Standards Institute","year":"2018","unstructured":"Clinical and Laboratories Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In CLSI document M7-A11, 7th ed","edition":"7"},{"key":"e_1_3_2_21_2","volume-title":"Guide for the Ccare and use of laboratory animals","year":"2011","unstructured":"National Research Council (US) Committee for the update of the guide for the care and use of laboratory animals, guide for the care and use of laboratory animals. 2011. In Guide for the Ccare and use of laboratory animals, 8th ed. Washington (DC).","edition":"8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8502(73)90006-2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2003.07.001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1947.150.1.70"},{"key":"e_1_3_2_25_2","first-page":"65","volume-title":"Biodefense research methodology and animal models","author":"Roy JR","year":"2006","unstructured":"Roy JR. 2006. Chapter 5 infectious disease aerobiology: aerosol challenge methods, p 65\u201379. In Swearengen J (ed), Biodefense research methodology and animal models"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00448-17"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00834-19"},{"key":"e_1_3_2_29_2","volume-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria","year":"2016","unstructured":"Clinical and Laboratory Standards Institute M45. 2016. In Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd Edition","edition":"3"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/iep.12013"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4873-4877.2004"},{"key":"e_1_3_2_32_2","unstructured":"World Health Organization (WHO). 2023. Antimicrobial resistance. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance#:~:text=Antibiotics%20are%20becoming%20increasingly%20ineffective the%20WHO%20priority%20pathogen%20list"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab190"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05724-11"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TBS-0001-2012"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00595-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00595-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:07:41Z","timestamp":1726672061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00595-24"}},"subtitle":[],"editor":[{"given":"Benjamin P.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,4]]}},"alternative-id":["10.1128\/aac.00595-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00595-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"2024-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00595-24"}}